Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""decitabine"" wg kryterium: Temat


Tytuł :
Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Autorzy :
Wei Y; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Xiong X; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Li X; The First Central Clinical College of Tianjin Medical University, Tianjin, China.
Lu W; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
He X; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Jin X; Nankai University School of Medicine, Tianjin, China.
Sun R; Nankai University School of Medicine, Tianjin, China.
Lyu H; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Yuan T; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Sun T; Department of Radiology, First Central Clinical College, Tianjin Medical University, Tianjin, China.
Zhao M; Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Sep; Vol. 112 (9), pp. 3636-3644. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Bridged Bicyclo Compounds, Heterocyclic/*adverse effects
Decitabine/*adverse effects
Hematopoietic Stem Cell Transplantation/*adverse effects
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*surgery
Myelodysplastic Syndromes/*drug therapy
Myelodysplastic Syndromes/*surgery
Sulfonamides/*adverse effects
Transplantation Conditioning/*methods
Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Decitabine/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Progression-Free Survival ; Prospective Studies ; Recurrence ; Sulfonamides/administration & dosage ; Transplantation, Homologous/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Autorzy :
Kadia TM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kanagal-Shamanna R; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Huang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pierce S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rausch C; Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Burger J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ferrajoli A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Popat U; Department of Stem Cell Transplant, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Estrov Z; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Verstovsek S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jabbour E; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kantarjian H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Aug 01; Vol. 96 (8), pp. 914-924. Date of Electronic Publication: 2021 May 26.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cladribine/*therapeutic use
Clofarabine/*therapeutic use
Cytarabine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cladribine/pharmacology ; Clofarabine/pharmacology ; Cytarabine/pharmacology ; Decitabine/pharmacology ; Humans ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Autorzy :
Xu R; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Li M; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Wu P; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Deng C; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Geng S; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Huang X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Weng J; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Du X; Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 312-320.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myelomonocytic, Chronic/*drug therapy
Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Azacitidine/administration & dosage ; Azacitidine/adverse effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Humans ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation.
Autorzy :
Ali N; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Prasad K; Amity Institute of Neuropsychology & Neurosciences, Amity University, Noida, UP 201303, India.
AlAsmari AF; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Alharbi M; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Rashid S; Department of Pharmacology & Toxicology, College of Pharmacy Girls Section, Prince Sattam Bin AbdulAziz University, Al kharj 11942, Saudi Arabia.
Kumar V; Amity Institute of Neuropsychology & Neurosciences, Amity University, Noida, UP 201303, India. Electronic address: .
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Nov 01; Vol. 190, pp. 636-648. Date of Electronic Publication: 2021 Sep 10.
Typ publikacji :
Journal Article
MeSH Terms :
Molecular Docking Simulation*
Molecular Dynamics Simulation*
Adaptor Proteins, Signal Transducing/*chemistry
COVID-19/*drug therapy
Coronavirus Nucleocapsid Proteins/*chemistry
DNA Helicases/*chemistry
Decitabine/*chemistry
Imatinib Mesylate/*chemistry
Poly-ADP-Ribose Binding Proteins/*chemistry
RNA Helicases/*chemistry
RNA Recognition Motif Proteins/*chemistry
RNA-Binding Proteins/*chemistry
SARS-CoV-2/*chemistry
Adaptor Proteins, Signal Transducing/antagonists & inhibitors ; Adaptor Proteins, Signal Transducing/metabolism ; COVID-19/metabolism ; Coronavirus Nucleocapsid Proteins/metabolism ; DNA Helicases/antagonists & inhibitors ; DNA Helicases/metabolism ; Decitabine/pharmacology ; Drug Delivery Systems ; Genomics ; Imatinib Mesylate/pharmacology ; Phosphoproteins/chemistry ; Phosphoproteins/metabolism ; Poly-ADP-Ribose Binding Proteins/antagonists & inhibitors ; Poly-ADP-Ribose Binding Proteins/metabolism ; RNA Helicases/antagonists & inhibitors ; RNA Helicases/metabolism ; RNA Recognition Motif Proteins/antagonists & inhibitors ; RNA Recognition Motif Proteins/metabolism ; RNA-Binding Proteins/antagonists & inhibitors ; RNA-Binding Proteins/metabolism ; SARS-CoV-2/metabolism
Czasopismo naukowe
Tytuł :
Epigenetic modulators combination with chemotherapy in breast cancer cells.
Autorzy :
Ari F; Science and Art Faculty, Department of Biology, Bursa Uludag University, Bursa, Turkey.
Napieralski R; Department of Obstetrics and Gynecology, Clinical Research Unit, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; Therawis Diagnostics GmbH, Munich, Germany.
Akgun O; Science and Art Faculty, Department of Biology, Bursa Uludag University, Bursa, Turkey.
Magdolen V; Department of Obstetrics and Gynecology, Clinical Research Unit, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Ulukaya E; Faculty of Medicine, Department of Clinical Biochemistry, Istinye University, Istanbul, Turkey.
Pokaż więcej
Źródło :
Cell biochemistry and function [Cell Biochem Funct] 2021 Jun; Vol. 39 (4), pp. 571-583. Date of Electronic Publication: 2021 Feb 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*pharmacology
Breast Neoplasms/*drug therapy
Decitabine/*pharmacology
Epigenesis, Genetic/*drug effects
Valproic Acid/*pharmacology
Antimetabolites, Antineoplastic/chemistry ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Decitabine/chemistry ; Drug Screening Assays, Antitumor ; Epigenesis, Genetic/genetics ; Female ; Humans ; Tumor Cells, Cultured ; Valproic Acid/chemistry
Czasopismo naukowe
Tytuł :
The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.
Autorzy :
Gleneadie HJ; School of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Present Address: MRC London Institute of Medical Sciences, Imperial College London, London, W12 0NN, UK.
Baker AH; School of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK.
Batis N; Institute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Bryant J; Institute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Jiang Y; Institute of Clinical Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Clokie SJH; West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's Hospital, Birmingham, B15 2TG, UK.
Mehanna H; Institute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Garcia P; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Gendoo DMA; Centre for Computational Biology, Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Roberts S; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Burley M; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Molinolo AA; Moores Cancer Center and Department of Pathology, University of California San Diego, La Jolla, CA, 92093, USA.
Gutkind JS; Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Scheven BA; School of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK.
Cooper PR; School of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Present Address: Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand.
Parish JL; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Khanim FL; Institute of Clinical Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Wiench M; School of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK. Electronic address: .
Pokaż więcej
Źródło :
Cancer letters [Cancer Lett] 2021 Mar 31; Vol. 501, pp. 172-186. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetaminophen/*administration & dosage
Antimetabolites, Antineoplastic/*administration & dosage
Decitabine/*administration & dosage
Head and Neck Neoplasms/*drug therapy
Leukemia, Myeloid/*drug therapy
Oxidative Stress/*drug effects
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Acetaminophen/pharmacology ; Animals ; Antimetabolites, Antineoplastic/pharmacology ; Cell Differentiation/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Decitabine/pharmacology ; Drug Synergism ; HL-60 Cells ; Head and Neck Neoplasms/metabolism ; Humans ; Leukemia, Myeloid/metabolism ; Male ; Mice ; Reactive Oxygen Species/metabolism ; Squamous Cell Carcinoma of Head and Neck/metabolism ; Superoxides/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia.
Autorzy :
Han P; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yu T; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Hou Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhao Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Liu Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Sun Y; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Wang H; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Xu P; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Li G; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Sun T; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Hu X; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Liu X; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Provincial Clinical Medicine Research Center for Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Li L; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Peng J; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Provincial Clinical Medicine Research Center for Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhou H; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Provincial Clinical Medicine Research Center for Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Hou M; Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.; Shandong Provincial Clinical Medicine Research Center for Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Feb 17; Vol. 12, pp. 630693. Date of Electronic Publication: 2021 Feb 17 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Blood Platelets/*pathology
Decitabine/*pharmacology
Programmed Cell Death 1 Receptor/*physiology
Purpura, Thrombocytopenic, Idiopathic/*drug therapy
T-Lymphocytes, Cytotoxic/*drug effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Apoptosis ; B7-H1 Antigen/physiology ; Decitabine/therapeutic use ; Female ; Humans ; Male ; Methylation ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Programmed Cell Death 1 Receptor/genetics ; Purpura, Thrombocytopenic, Idiopathic/etiology ; Purpura, Thrombocytopenic, Idiopathic/immunology ; T-Lymphocytes, Cytotoxic/physiology ; Young Adult
Czasopismo naukowe
Tytuł :
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Autorzy :
Gu X; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Tohme R; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Tomlinson B; Department of Hematology and Oncology, University Hospitals, Cleveland, OH, USA.
Sakre N; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hasipek M; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Durkin L; Department of Clinical Pathology, Tomsich Pathology Institute, Cleveland Clinic, Cleveland, OH, USA.
Schuerger C; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Grabowski D; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Zidan AM; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Radivoyevitch T; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Hong C; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
Carraway H; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hamilton B; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Sobecks R; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Patel B; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Jha BK; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hsi ED; Department of Clinical Pathology, Tomsich Pathology Institute, Cleveland Clinic, Cleveland, OH, USA.
Maciejewski J; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Saunthararajah Y; Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. .; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Apr; Vol. 35 (4), pp. 1023-1036. Date of Electronic Publication: 2020 Aug 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Drug Resistance, Neoplasm*/genetics
Antimetabolites, Antineoplastic/*pharmacology
Azacitidine/*pharmacology
Decitabine/*pharmacology
Metabolic Networks and Pathways/*drug effects
Pyrimidines/*metabolism
Animals ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Cell Line, Tumor ; DNA (Cytosine-5-)-Methyltransferase 1/genetics ; DNA (Cytosine-5-)-Methyltransferase 1/metabolism ; DNA Methylation ; Decitabine/therapeutic use ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Humans ; Mice ; Uridine Kinase/genetics ; Uridine Kinase/metabolism
Czasopismo naukowe
Tytuł :
Epigenetic Modification of MicroRNA-219-1 and Its Association with Glioblastoma Multiforme.
Autorzy :
Ghasemi A; Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, 1417613151, Iran. .
Mohammadi A; Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, 1449614535, Iran. .
Fallah S; Department of Clinical Biochemistry, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, 1449614535, Iran. .
Pokaż więcej
Źródło :
Biochemistry. Biokhimiia [Biochemistry (Mosc)] 2021 Apr; Vol. 86 (4), pp. 420-432.
Typ publikacji :
Journal Article
MeSH Terms :
Epigenesis, Genetic*
Decitabine/*pharmacology
Glioblastoma/*genetics
MicroRNAs/*genetics
Adult ; Aged ; Cell Line, Tumor ; DNA Methylation ; Decitabine/therapeutic use ; Female ; Gene Expression Regulation, Neoplastic ; Glioblastoma/drug therapy ; Glioblastoma/metabolism ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Effects of 5-Aza-2'-deoxycytidine on hormone secretion and epigenetic regulation in sika deer ovarian granulosa cells.
Autorzy :
Chen X; Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun, China.
Xing M; State Key laboratory of Special Economic Animal Molecular Biology, Changchun, China.
Pokaż więcej
Źródło :
Reproduction in domestic animals = Zuchthygiene [Reprod Domest Anim] 2021 Feb; Vol. 56 (2), pp. 360-369. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article
MeSH Terms :
Decitabine/*pharmacology
Deer/*physiology
Granulosa Cells/*drug effects
Animals ; Apoptosis/drug effects ; Cell Cycle/drug effects ; DNA Methylation/drug effects ; Decitabine/administration & dosage ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/pharmacology ; Epigenesis, Genetic/drug effects ; Estradiol/metabolism ; Female ; Progesterone/metabolism
Czasopismo naukowe
Tytuł :
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Autorzy :
Cortes J; Department of Leukemia, Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA. .
Podoltsev N; Department of Internal Medicine, Hematology Section, Yale University School of Medicine, New Haven, CT, USA.
Kantarjian H; Department of Leukemia, Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Borthakur G; Department of Leukemia, Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Zeidan AM; Department of Internal Medicine, Hematology Section, Yale University School of Medicine, New Haven, CT, USA.
Stahl M; Department of Internal Medicine, Hematology Section, Yale University School of Medicine, New Haven, CT, USA.
Taube T; Boehringer Ingelheim International GmbH, Biberach, Germany.
Fagan N; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Rajeswari S; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Uy GL; Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Jan; Vol. 113 (1), pp. 92-99. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Cell Cycle Proteins*/genetics
Cell Cycle Proteins*/metabolism
Cell Cycle Proteins*/physiology
Gene Expression*
Protein-Serine-Threonine Kinases*/genetics
Protein-Serine-Threonine Kinases*/metabolism
Protein-Serine-Threonine Kinases*/physiology
Proto-Oncogene Proteins*/genetics
Proto-Oncogene Proteins*/metabolism
Proto-Oncogene Proteins*/physiology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Decitabine/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Pteridines/*administration & dosage
Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Decitabine/adverse effects ; Decitabine/pharmacokinetics ; Dose-Response Relationship, Drug ; Febrile Neutropenia/chemically induced ; Feeding and Eating Disorders/chemically induced ; Female ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Molecular Targeted Therapy ; Pteridines/adverse effects ; Pteridines/pharmacokinetics ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
Autorzy :
Zhou S; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tremblay D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Najfeld V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Li L; Department of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Moshier E; Department of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA, .
Pokaż więcej
Źródło :
Acta haematologica [Acta Haematol] 2021; Vol. 144 (1), pp. 48-57. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Decitabine/*therapeutic use
Myeloproliferative Disorders/*diagnosis
Myeloproliferative Disorders/*drug therapy
Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Biomarkers ; Chromosome Aberrations ; Combined Modality Therapy ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Female ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Mutation ; Myeloproliferative Disorders/etiology ; Myeloproliferative Disorders/mortality ; Neoplasm Staging ; Prognosis ; Retreatment ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Autorzy :
Montesinos P; Hematology Department, Hospital Universitari i Politècnic La Fe, València, Spain. .; CIBERONC, Instituto Carlos III, Madrid, Spain. .
Roboz GJ; Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA.
Bulabois CE; CHU Grenoble, Service d'hématologie Clinique, Grenoble, France.
Subklewe M; Department of Medicine III, University Hospital Ludwig-Maximillians-Universität München, Munich, Germany.
Platzbecker U; Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany.
Ofran Y; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel.
Papayannidis C; Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology 'L. and A. Seragnoli', University of Bologna, Bologna, Italy.
Wierzbowska A; Department of Hematology, Medical University of Lodz, Lodz, Poland.
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Pusan, Republic of Korea.
Doronin V; Department of Hematology and Chemotherapy, City Clinical Hospital No. 40, Moscow, Russian Federation.
Deneberg S; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Yeh SP; Division of Hematology-Oncology, China Medical University Hospital, Taichung, Taiwan.
Ozcan MA; Department of Hematology, Faculty of Medicine, Dokuz Eylul Universıty, Izmir, Turkey.
Knapper S; Cardiff University School of Medicine, Cardiff, UK.
Cortes J; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
Pollyea DA; Division of Hematology, School of Medicine, University of Colorado, Aurora, CO, USA.
Ossenkoppele G; Department of Hematology, Amsterdam University Medical Center, VUMC, Amsterdam, The Netherlands.
Giralt S; Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Xiu L; Janssen Research and Development, Raritan, NJ, USA.
Singh I; Janssen Research and Development, Spring House, PA, USA.
Huang F; Janssen Research and Development, Spring House, PA, USA.
Larsen JS; Janssen Research and Development, Los Angeles, CA, USA.
Wei AH; Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 62-74. Date of Electronic Publication: 2020 Mar 16.
Typ publikacji :
Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Decitabine/*therapeutic use
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Decitabine/pharmacokinetics ; Drug Monitoring ; Female ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Prognosis ; Research Design ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.
Autorzy :
Meng T; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.
Yao Y; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xu Y; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Xue S; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Han Y; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Tang X; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Qiu H; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Sun A; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Wu D; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Zhang Y; Department of Hematology, The Second People's Hospital of Huai'an, Huai'an, China.
Wang Y; National Clinical Research Center for Hematologic Disease, The First Affiliated Hospital of Soochow University, Suzhou, China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 834-837. Date of Electronic Publication: 2020 Aug 14.
Typ publikacji :
Letter
MeSH Terms :
Aclarubicin/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cytarabine/*therapeutic use
Decitabine/*therapeutic use
Granulocyte Colony-Stimulating Factor/*therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Salvage Therapy/*methods
Aclarubicin/pharmacology ; Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cytarabine/pharmacology ; Decitabine/pharmacology ; Female ; Granulocyte Colony-Stimulating Factor/pharmacology ; Humans ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Survival Analysis
Opinia redakcyjna
Tytuł :
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Autorzy :
Gao L; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Zhang Y; Department of Health Statistics, College of Military Preventive Medicine, Army Medical University, Chongqing, China.
Wang S; Department of Hematology, General Hospital of Kunming Military Region of the People's Liberation Army (PLA), Kunming, China.
Kong P; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Su Y; Department of Hematology, General Hospital of Chengdu Military Region of the PLA, Chengdu, China.
Hu J; Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jiang M; Department of Hematology, the Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Bai H; Department of Hematology, General Hospital of Lanzhou Military Region of the PLA, Lanzhou, China.
Lang T; Department of Hematology, Xinjiang Provincial People's Hospital, Urumqi, China.
Wang J; Department of Hematology, Affiliated Hospital of Guiyang Medical University, Guiyang, China.
Liu L; Department of Hematology, Tangdu Hospital, Forth Military Medical University (Air Force Medical University), Xi'an, China.
Yang T; Department of Hematology, Yunnan Provincial People's Hospital, Kunming, China.
Huang X; Department of Hematology, Sichuan Provincial People's Hospital, Chengdu, China.
Liu F; Department of Hematology, General Hospital of Chengdu Military Region of the PLA, Chengdu, China.
Lou S; Department of Hematology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Liu Y; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Zhang C; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Liu H; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Gao L; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Liu J; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Zhu L; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Wen Q; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Chen T; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Wang P; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Rao J; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Mao M; Department of Hematology, Xinjiang Provincial People's Hospital, Urumqi, China.
Wang C; Department of Hematology, General Hospital of Lanzhou Military Region of the PLA, Lanzhou, China.
Duan X; Department of Hematology, the Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Luo L; Department of Hematology, General Hospital of Kunming Military Region of the People's Liberation Army (PLA), Kunming, China.
Peng X; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Cassady K; Departments of Diabetes Immunology and Hematology/Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA.
Zhong JF; Department of Otolaryngology, Keck School of Medicine, University of Southern California, CA.
Zhang X; Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 20; Vol. 38 (36), pp. 4249-4259. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Decitabine/*therapeutic use
Filgrastim/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Adolescent ; Adult ; Antimetabolites, Antineoplastic/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Child ; Child, Preschool ; Decitabine/pharmacology ; Female ; Filgrastim/pharmacology ; Humans ; Male ; Middle Aged ; Prognosis ; Recurrence ; Risk Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
Autorzy :
Ai Y; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Lu X; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Zhu T; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Zhu Y; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Liu H; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Sun S; Department of Pediatrics, West China Second University Hospital, Sichuan University.; Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Dec 11; Vol. 99 (50), pp. e23606.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myelomonocytic, Juvenile/*diagnosis
Neoplasm Recurrence, Local/*diagnosis
Antimetabolites, Antineoplastic/administration & dosage ; Combined Modality Therapy ; Decitabine/administration & dosage ; Diagnosis, Differential ; Hematopoietic Stem Cell Transplantation ; Humans ; Infant ; Leukemia, Myelomonocytic, Juvenile/therapy ; Male ; Neoplasm Recurrence, Local/therapy
Czasopismo naukowe
Tytuł :
Increased Circulating CD4 Cells and IgG4 Levels in Patients with Myelodysplastic Syndrome with Autoimmune Diseases.
Autorzy :
Xiao, Na (AUTHOR)
He, Xin (AUTHOR)
Niu, Haiyue (AUTHOR)
Yu, Hong (AUTHOR)
Cui, Ningbo (AUTHOR)
Li, Hongzhao (AUTHOR)
Yan, Li (AUTHOR)
Shao, Zonghong (AUTHOR)
Xing, Limin (AUTHOR)
Wang, Huaquan (AUTHOR)
Pokaż więcej
Źródło :
Journal of Immunology Research. 10/15/2021, p1-9. 9p. 2 Charts, 5 Graphs.
Czasopismo naukowe
Tytuł :
Exposure to hypomethylating 5-aza-2'-deoxycytidine (decitabine) causes rapid, severe DNA damage, telomere elongation and mitotic dysfunction in human WIL2-NS cells.
Autorzy :
Bull C; CSIRO Health & Biosecurity, Gate 13 Kintore Avenue, Adelaide, South Australia, Australia; School of Molecular and Biomedical Sciences, University of Adelaide, North Terrace, Adelaide, South Australia, Australia. Electronic address: .
Mayrhofer G; School of Molecular and Biomedical Sciences, University of Adelaide, North Terrace, Adelaide, South Australia, Australia.
Fenech M; CSIRO Health & Biosecurity, Gate 13 Kintore Avenue, Adelaide, South Australia, Australia.
Pokaż więcej
Źródło :
Mutation research. Genetic toxicology and environmental mutagenesis [Mutat Res Genet Toxicol Environ Mutagen] 2021 Aug-Sep; Vol. 868-869, pp. 503385. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Damage/*drug effects
DNA Methylation/*drug effects
Decitabine/*pharmacology
Telomere/*drug effects
Biomarkers/metabolism ; Cell Line ; Chromosomal Instability/drug effects ; Cytokinesis/drug effects ; Humans ; Lymphocytes/drug effects ; Micronucleus Tests/methods ; Mitosis/drug effects
Czasopismo naukowe
Tytuł :
Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study.
Autorzy :
Xu W; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Ye L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Mei C; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Zhou XP; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Ren Y; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Ma L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Ye X; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Lu C; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Tong HY; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, PR China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, PR China.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Aug; Vol. 62 (8), pp. 1920-1929. Date of Electronic Publication: 2021 Mar 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/drug therapy
Myelodysplastic Syndromes*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Decitabine/therapeutic use ; Humans ; Idarubicin/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł :
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Autorzy :
DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maiti A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rausch CR; Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naqvi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kadia TM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ohanian M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Issa GC; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Montalban-Bravo G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Short NJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yilmaz M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bose P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour EJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Burger JA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kornblau SM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thompson PA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Estrov Z; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Verstovsek S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ferrajoli A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weirda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang SA; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konoplev S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen Z; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pierce SA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ning J; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qiao W; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreeff M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Welch JS; Division of Hematology & Oncology, Washington University School of Medicine, St Louis, MO, USA.
Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konopleva MY; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Oct; Vol. 7 (10), pp. e724-e736. Date of Electronic Publication: 2020 Sep 05.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Sulfonamides/*therapeutic use
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies